Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025
The data will be provided in a morning press release and presented during the webcast. Details on how to access the live webcast of the call will be available in the morning press release and on the Nektar website at www.nektar.com. A replay of the webcast will be available for at least 30 days following the event.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
For Investors:
Corey Davis, PhDLifeSci Advisors212-915-2577cdavis@lifesciadvisors.com
For Media:
Madelin HawtinLifeSci Communications603-714-2638mhawtin@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-top-line-data-from-the-16-week-induction-period-in-rezolve-ad-phase-2b-study-of-rezpegaldesleukin-a-regulatory-t-cell-proliferator-in-atopic-dermatitis-on-june-24-2025-302488592.html
SOURCE Nektar Therapeutics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
22 minutes ago
- Forbes
Sunrun Stock To $7?
CHONGQING, CHINA - MAY 04: In this photo illustration, the logo of Sunrun Inc. is displayed on a ... More smartphone screen with a stock market chart in the background, on May 04, 2025, in Chongqing, China. (Photo illustration by) Sunrun (NASDAQ: RUN) is the leading residential solar installer in the U.S. based on market share. The company's position has become increasingly unstable due to a mix of policy changes, financial pressures, and shifting market dynamics. There's more to consider – With a market capitalization of $2.5 billion, Sunrun has experienced a 36% loss of value over the last year. Investors need to recognize the company's susceptibility to economic downturns, which was evident during the Covid-19 crisis when its stock fell by about 40% in just a few quarters. This historical context raises the possibility that Sunrun's current share price of $11 might decline to approximately $7 if similar market conditions arise again. Nevertheless, for investors aiming for lower volatility than individual stocks, the Trefis High Quality portfolio offers an alternative, having outperformed the S&P 500 and delivered returns that exceed 91% since its inception. Separately, see Is Intel Stock A Buy Now? Why Is It Relevant Now? Recent actions from both the legislative and executive branches have sped up the expiration of important federal tax credits—namely, the 25D Residential Solar Credit and the 48E Investment Tax Credit—shortening the opportunity for Sunrun to take advantage of these vital incentives. An executive order enacted on July 8 complicates the situation further by redefining the term 'under construction,' introducing new compliance challenges. Concurrently, the imposition of substantial tariffs on imported solar equipment jeopardizes cost structures and profit margins. These changes fundamentally impact Sunrun's business model, which heavily relies on tax credits to back its leasing and power purchase agreements. As these incentives wane and operational costs escalate, the company's capability to sustain competitive pricing and profitability is increasingly at risk. How resilient is RUN stock during a downturn? Historically, Sunrun has lagged behind the S&P 500 during market downturns, underscoring its vulnerability to macroeconomic shocks. In the 2022 inflation-driven selloff, RUN tumbled 67.4%, significantly worse than the S&P 500's 25.4% decline, and it has not yet regained its previous highs, presently trading around $10.90. In the downturn triggered by Covid, RUN dropped 38.7% but bounced back swiftly. While the stock can recover, its historical performance indicates high volatility and limited downside resilience. Our dashboard How Low Can Stocks Go During A Market Crash captures the performance of key stocks during and after the last six market crashes. Protecting Wealth No longer merely a solar stock, Sunrun now serves as a high-stakes indicator of the trajectory for rooftop solar as federal policy shifts become less predictable. Although the company is actively adapting—expanding into energy storage, changing billing models, and tweaking its supply chain—investors continue to be concerned about the pace and effectiveness of these strategic adjustments. With increasing regulatory challenges and expiring incentives, the market is closely monitoring whether Sunrun can adjust quickly enough to maintain growth and protect its margins. RUN stock is currently trading at 1.1x price-to-sales, below its 3-year average of 1.5x and considerably less than the S&P 500 average of 3.1x. While this might imply a discount, it does not categorize it as 'deep value.' Sunrun continues to be valued as a growth company, and when growth appears uncertain, justifying that premium becomes more difficult. Considering the wider economic uncertainties, ask yourself the question: Do you wish to retain Sunrun stock now? Would you feel compelled to sell if it begins to decline to $8, $7, or even lower? Holding onto a declining stock is never easy. Trefis collaborates with Empirical Asset Management—a Boston-based wealth manager—whose asset allocation strategies yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Empirical has integrated the Trefis HQ Portfolio into this asset allocation strategy to offer clients better returns with reduced risk compared to the benchmark index; providing a less turbulent experience, as demonstrated in the HQ Portfolio performance metrics.
28 minutes ago
World shares are mixed as investors focus on tariffs and earnings
BANGKOK -- World shares were mixed on Monday as investors focused on tariffs and corporate earnings updates. An announcement over the weekend by U.S. President Donald Trump that he plans 30% tariffs on goods from Mexico and the European Union had a modest immediate impact, as analysts said they expected progress toward trade deals before an Aug. 1 deadline. Trump detailed the planned tariffs Saturday in letters posted to his social media account. The Mexican peso weakened slightly against the dollar, trading at 18.6 pesos to the dollar. Chinese shares advanced after the government reported that exports rose last month as a truce in a tariffs war prompted a surge in orders ahead of an Aug. 12 deadline for reaching a new trade deal with Washington. Hong Kong's Hang Seng gained 0.3% to 24,091.45, while the Shanghai Composite index also was up 0.3%, at 3,519.65. Tokyo's Nikkei 225 index slipped 0.3% to 39,459.62, while the Kospi in South Korea jumped 0.8% to 3,202.03. In Australia, the S&P/ASX 200 edged 0.1% lower to 8,570.40. Taiwan's benchmark lost 0.6%. On Friday, a modest pullback for U.S. stocks left major stock indexes on Wall Street in the red for the week. The S&P 500 closed 0.3% lower, at 6,259.75, a day after setting a record high. The Dow Jones Industrial Average dropped 0.6% to 44,371.51, and the Nasdaq composite gave up 0.2% to 20,585.53 after drifting between small gains and losses much of the day. The tech-heavy index was coming off its own all-time high on Thursday. The selling capped an uneven week in the market as Wall Street kept an eye on the Trump administration's rollout of new tariff threats against trading partners like Canada and looked ahead to the upcoming corporate earnings reporting season. Trump said in a letter Thursday that he will raise taxes on many imported goods from Canada to 35%, deepening the rift between the longtime North American allies. The letter to Canadian Prime Minister Mark Carney was an aggressive increase to the top 25% tariff rates that Trump first imposed in March. The administration had initially set Wednesday as a deadline for countries to make deals with the U.S. or face heavy increases in tariffs. But with just two trade deals announced since April, one with the United Kingdom and one with Vietnam, the window for negotiations has been been extended to Aug. 1. Trump also floated this week that he would impose tariffs of as much as 200% on pharmaceutical drugs and place a 50% tariff on copper imports, matching the rates charged on steel and aluminum. The initial rollout of Trump's tariff policies in the spring roiled financial markets. But they have been relatively stable in recent weeks, suggesting investors have adjusted to the unpredictability of his sudden policy shifts. Markets are set to shift their focus to quarterly earnings over the next few weeks. JPMorgan Chase, Wells Fargo and Citigroup are among big banks due to report their results on Tuesday. Shares in aviation company Red Cat Holdings jumped 26.4% Friday after Defense Secretary Pete Hegseth issued orders aimed at ramping up production and deployment of drones. Bitcoin climbed to another all-time high, rising 3.6% early Monday to $121,914, according to CoinDesk. Bitcoin's price has jumped amid bullish momentum across risk assets and coincides with Nvidia's surge to a $4 trillion valuation. The U.S. Congress' Crypto Week starts Monday. Lawmakers will debate a series of bills that could define the regulatory framework for the industry. In other dealings early Monday, U.S. benchmark crude oil gained 45 cents to $68.90 per barrel. Brent crude, the international standard, was up 44 cents at $70.80 per barrel. The dollar slipped to 147.22 Japanese yen from 147.38 yen. The euro fell to $1.1685 from $1.1692.
Yahoo
39 minutes ago
- Yahoo
Exact Sciences Schedules Second Quarter 2025 Earnings Call
MADISON, Wis., July 14, 2025--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2025 webcast & conference call details Date: Wednesday, August 6, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at Telephone: Domestic callers, dial 888-330-2384International callers, dial +1 240-789-2701 Access code for both domestic and international callers: 4437608 A replay of the webcast will be available at The webcast, conference call, and replay are open to all interested parties. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company's growing portfolio includes well-established brands such as Cologuard® and Oncotype DX®, along with innovative solutions like Oncodetect™ for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit follow @ExactSciences on X, or connect on LinkedIn and Facebook. View source version on Contacts Investor Contact:Derek Leckow608-893-0009investorrelations@ 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
